5-Fluorouracil - CAS:51-21-8

您当前的位置：

5-Fluorouracil (Synonyms:5-氟脲嘧啶; 5-FU)

目录号 : KM17926 CAS No. : 51-21-8 纯度 : 98%

产品说明书产品使用指南

5-Fluorouracil (5-FU) 是一种尿嘧啶的类似物 (nucleoside antimetabolite/analog)，是一种有效的抗肿瘤药。5-Fluorouracil 通过抑制胸苷酸合成酶影响嘧啶的合成，从而耗尽细胞内dTTP 池。5-Fluorouracil 诱导细胞凋亡 (apoptosis)，可用作化学敏化剂。5-Fluorouracil 还可抑制 HIV 病毒。5-Fluorouracil (5-FU) 可破坏外泌体特异性的 rRNA。

规格	价格	是否有货
200mg		In-stock
1g		In-stock
5g		In-stock
10g	询价	In-stock
50g	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

5-Fluorouracil In-stock
Chloroquine In-stock
Dimethyl fumarate In-stock
Limonin In-stock
3-Deazaadenosine hydrochloride In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer. 5-Fluorouracil also inhibits HIV.

体外研究

5-Fluorouracil (5-Fu) and NSC 123127 (Dox) show synergistic anticancer efficacy. The IC₅₀ value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively. In 5-fluorouracil (5-FU) and CDDP treated NFBD1-inhibited NPC cells, the NFBD1 expression in NPC CNE1 cell lines is depleted using lentivirus-mediated short hairpin RNA, and the sensitivity of these cells is elevated. NFBD1 knockdown leads to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells.

体内研究

5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility.

分子式

C₄H₃FN₂O₂

分子量

130.08

CAS号

51-21-8

中文名称

5-氟脲嘧啶；双喃呋啶

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (768.76 mM; Need ultrasonic)

H₂O : 20 mg/mL (153.75 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	7.6876 mL	38.4379 mL	76.8758 mL
5 mM	1.5375 mL	7.6876 mL	15.3752 mL
10 mM	0.7688 mL	3.8438 mL	7.6876 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline
Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution
2.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution
3.

请依序添加每种溶剂： 5% DMSO 95% saline
Solubility: 2.5 mg/mL (19.22 mM); Clear solution; Need ultrasonic